Intersect ENT Lands $30M From Norwest, Kleiner, USVP & More For Its Innovative Sinus Drug & Device Combo

In August 2011, Intersect won approval from the FDA for Propel, which, simply put, is a stent that doctors implant in the sinuses after surgery to help keep them open. The cool part is that, over time, the stent absorbs into the patient's body post-surgery (so that follow-up surgery isn't required), slowly releasing a steroid to help control local inflammation, according to Medgadget. In the fall of last year, the company won approval again for the Propel Mini, a miniaturized version of its flagship product designed for "less extensive surgeries," Medgadget says.

Source: http://feedproxy.google.com/~r/Techcrunch/~3/MOWvOOQwBkY/

camilla belle Robert Bork instagram mark sanchez christina aguilera Mayan End Of The World Olivia Black